IP Verse

Dosage Form Containing Oxycodone And Naloxone - EP3578173

The patent EP3578173 was granted to Euro Celtique on Oct 26, 2022. The application was originally filed on Feb 28, 2006 under application number EP19167974A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3578173

EURO CELTIQUE
Application Number
EP19167974A
Filing Date
Feb 28, 2006
Status
Granted And Under Opposition
Sep 23, 2022
Grant Date
Oct 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHYPHARMJul 26, 2023REGIMBEAUADMISSIBLE
JP PEELJul 26, 2023PEELADMISSIBLE
PUREN PHARMAJul 26, 2023HAMM & WITTKOPPADMISSIBLE
DEVELCO PHARMA SCHWEIZOct 26, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
SANDOZOct 26, 2022TER MEER STEINMEISTER & PARTNERWITHDRAWN

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONDE4325465
DESCRIPTIONEP0352361
DESCRIPTIONUS3773955
DESCRIPTIONUS3966940
DESCRIPTIONUS4457933
DESCRIPTIONUS4582835
DESCRIPTIONUS6258042
DESCRIPTIONWO03073937
DESCRIPTIONWO03084520
EXAMINATIONWO03084520
OPPOSITIONEP0352361
OPPOSITIONEP2258353
OPPOSITIONEP2962686
OPPOSITIONEP3578173
OPPOSITIONUS3966940
OPPOSITIONUS4457933
OPPOSITIONWO02092060
OPPOSITIONWO03084504
OPPOSITIONWO03084520
OPPOSITIONWO2006089973
OPPOSITIONWO9825613
OTHEREP1855657
OTHERWO03084504
OTHERWO03084520
SEARCHDE4325465
SEARCHEP1604666
SEARCHWO02092060
SEARCHWO03007802
SEARCHWO03084504

Non-Patent Literature (NPL) Citations (65) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Die Schmerzbehandlung von Tumorpatienten", Supportive MaBnahmen in der Onkologie, Thieme, (19940000), vol. 3-
DESCRIPTION- ZECH, D.; GROND, S.; LYNCH, J.; HERTEL, D.; LEHMANN, K., "Validation of World Health Organisation Guidelines for Cancer Pain Relief: a 10-year prospective study", Pain, (19950000), vol. 63, pages 65 - 76-
OPPOSITION- Anonymous, "Fachinformation TARGIN ® 5 mg/2,5 mg, 10 mg/5 mg, 20 mg/10 mg, 40 mg/20 mg", Fachinformation, MunidiPharma, (20230901), pages 1 - 9, Fachinformation, URL: https://www.fachinfo.de/api/public/fachinfo/pdf/009851, (20240409), XP093149594-
OPPOSITION- Anonymous, "ICH E9 Note for Guidance on Statistical Principles for Clinical Trials", eurpean medicines agency, (19980901), pages 1 - 37, XP055492770-
OPPOSITION- Anonymous, "Naloxon", Europäisches Arzneibuch. 4. Auflage (Ph.Eur. 4),, (20020101), pages 2442 - 2443, XP055464234-
OPPOSITION- Anonymous, "Physicans' Desk Reference® (passage)", Physicans' Desk Reference®, 59th ed., (20050101), pages 2818 - 2824, ISBN 978-1-56363-497-0, XP055978869-
OPPOSITION- Anonymous, "Purdue Pharma", Anonymous, Lori Murray, Physicians Desk Reference, Thomson PDR, (20050301), pages 2818 - 2822, ISBN 1-56363-497-X, XP093094496-
OPPOSITION- A. WILLWEBER-STRUMPF, "E5 Missbrauch, Abhängigkeit", A. WILLWEBER-STRUMPF, Zenz/Jurna, Lehrbuch der Schmerztherapie, DE, Wissenschaftliche Verlagsgesellschaft mbH, (20010101), pages 875 - 885, ISBN 3-8047-1805-1, XP009553342-
OPPOSITION- "Chapters 2 and 11.1.3.1", Zenz Michael, Jurna Ilmar, Lehrbuch der Schmerztherapie - Grundlagen, Theorie und Praxis für Aus- und Weiterbildung, 2. Auflage, (20010101), pages 1pp, IV, 255 - 280, 462, 463, ISBN 3-8047-1805-1, XP055411579-
OPPOSITION- Cluin-Su Yuan, Marco Pappagallo, "Introduction", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 1 - 4, ISBN 978-0-7890-2128-1, XP009553331-
OPPOSITION- CULPEPPER-MORGAN J A, ET AL., "TREATMENT OF OPIOID-INDUCED CONSTIPATION WITH ORAL NALOXONE: A PILOT STUDY", Clinical Pharmacology and Therapeutics, Nature Publishing Group, US, US , (19920101), vol. 52, no. 01, ISSN 0009-9236, pages 90 - 95, XP009062715-
OPPOSITION- Europaisches Arzneibuch. 4. Auflage (Ph.Eur. 4), (20020101), pages 2442 - 2443, XP055464234-
OPPOSITION- J. JAGE, I. JURNA, "2 Opioidanalgetika", Lehrbuch der Schmerztherapie, Wissenschaftliche Verlagsgesellschaft mbH, (20010101), pages 255 - 280, ISBN 3-8047-1805-1, XP009553338-
OPPOSITION- J. Jage, I. Jurna, "Opioidanalgetika", J. Jage, I. Jurna, Zenz Michael, Jurna Ilmar, Lehrbuch der Schmerztherapie, Grundlagen, Theorie und Praxis für Aus- und Weiterbildung, (20010101), pages 1pp, IV, 255 - 463, ISBN 978-3-8047-1805-0, XP055411579-
OPPOSITION- J. Jage, I. Jurna, "Opioidanalgetika", Lehrbuch der Schmerztherapie, Grundlagen, Theorie und Praxis für Aus- und Weiterbildung, (20010101), pages 1pp, IV, 255 - 463, ISBN 978-3-8047-1805-0, XP055411579-
OPPOSITION- Joseph E Foss, William K. Schmidt, "Chapter 11. Management of Opioid-Induced BowelDysfunction and Postoperative Ileus: Potential Role of Alvimopan", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 223 - 249, ISBN 978-0-7890-2128-1, XP009553337-
OPPOSITION- J. SORGE, "11 Medikamentöse Schmerztherapie", J. SORGE, Zenz/Jurna, Lehrbuch der Schmerztherapie, DE, Wissenschaftliche Verlagsgesellschaft mbH, (20010101), pages 457 - 473, ISBN 3-8047-1805-1, XP009553339-
OPPOSITION- Keri L. Fakata, Arthur G. Lipman, "Chapter 1. Gastrointestinal Opioid Physiology and Pharmacology", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 7 - 28, ISBN 978-0-7890-2128-1, XP009553332-
OPPOSITION- Leyendecker Petra, "Einfluss der gleichzeitigen Applikation von Oxycodon und Naloxon auf Analgesie und Opioid-induzierte gastrointestinale Dysfunktion ", Dissertation, (20080101), pages 1 - 146, XP093094291-
OPPOSITION- M. Hopp, C Ruckes , M Friedman , J Miller , P Leyendecker , K Reimer , W Fleischer, "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Der Schmerz, (20051001), vol. 19, pages 1 - 3, XP055642010-
OPPOSITION- M. Hopp et al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Mundipharma research, Bremen, (20051001), page 1, XP055641999-
OPPOSITION- M. Hopp, Et Al., "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Mundipharma research, Bremen, Bremen , (20051001), page 1, Mundipharma research, (20191113), XP055641999-
OPPOSITION- M. Hopp et al., "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Der Schmerz, (20051001), vol. 19, page S103, XP055642010-
OPPOSITION- M. Hopp, Et Al., "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", Poster 11.2 presented at the German Pain Congress, (20050101), Poster 11.2 presented at the German Pain Congress, (20190426), XP055583669-
OPPOSITION- M. Hopp et al., "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", Poster 11.2 presented at the German Pain Congress, (20050101), XP055583669-
OPPOSITION- M. Hopp, "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Bremen , (20051001), page 1, Mundipharma research, (20191113), XP055641999-
OPPOSITION- M. Hopp, "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Mundipharma research, Bremen, Bremen , (20051001), page 1, Mundipharma research, (20191113), XP055641999-
OPPOSITION- M. Hopp, "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Der Schmerz, (20051001), vol. 19, page 103, XP055642010-
OPPOSITION- M. Hopp, "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Der Schmerz, (20051001), vol. 19, page s103, XP055642010-
OPPOSITION- M. Hopp, "P11.3 The combination of naloxone with prolonged release (PR) oxycodobne is able to reduce opioid-induced constipation - results of clinical study", Der Schmerz, (20051001), vol. 19, pages 1 - 3, XP055642010-
OPPOSITION- M. Hopp, "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", (20050101), pages 1 - 1, Poster 11.2 presented at the German Pain Congress, (20190426), XP055583669-
OPPOSITION- M. Hopp, "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", (20050101), Poster 11.2 presented at the German Pain Congress, (20190426), XP055583669-
OPPOSITION- M. Hopp, "The combination of naloxone with prolonged release (PR) oxycodone is able to reduce opioid-induced constipation-Results of a clinical study", Poster 11.2 presented at the German Pain Congress, (20050101), XP055583669-
OPPOSITION- Michael Hopp , Christian Ruckes , Michael Friedman , Petra Leyendecker , Wolfgang Fleischer , Karen Reimer, "Influence of an addition of naloxone to prolonged release (PR) oxycodone on the analgesic efficacy - results of a clinical study", Mundipharma research, Bremen , (20051001), pages 1 - 1, XP055641999-
OPPOSITION- M. STRUMPF, M. ZENZ, "13 Stufenschema, Betäubungsmittelverschreibungsverordnung (BtMVV)", M. STRUMPF, M. ZENZ, Zenz/Jurna, Lehrbuch der Schmerztherapie, DE, Wissenschaftliche Verlagsgesellschaft mbH, (20010101), pages 485 - 498, ISBN 3-8047-1805-1, XP009553340-
OPPOSITION- Mundipharma Gmbh, "Optimization of Naloxone - Oxycodone ratio in pain patients", Study Protocol OXN 2401, (20011207), pages 1 - 38, XP055298247-
OPPOSITION- Mundipharma Gmbh, "Optimization of Naloxone - Oxycodone ratio in pain patients", Study Protocol OXN 2401, pages 1 - 38, XP055298247-
OPPOSITION- Nigel P. Sykes, "Chapter 5. Opioid Bowel Dysfunction in Palliative Care", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 69 - 100, ISBN 978-0-7890-2128-1, XP009553334-
OPPOSITION- Nigel P. Sykes, "Chapter 9. Using Oral Naloxone in Management of Opioid Bowel Dysfunction", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 175 - 195, ISBN 978-0-7890-2128-1, XP009553335-
OPPOSITION- Physicans' Desk Reference®, 59th ed., (20050101), pages 2818 - 2824, ISBN 978-1-56363-497-0, XP055978869-
OPPOSITION- "Physicans' Desk Reference® (passage)", Anonymous, Physicans' Desk Reference®, 59th ed., (20050101), pages 2818 - 2822, ISBN 978-1-56363-497-0, XP055978869-
OPPOSITION- Sangeeta R. Mehendale, Chiin-Sii Yuan, "Chapter 2. Pathophysiology of Opioid-Induced Bowel Dysfunction", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 29 - 44, ISBN 978-0-7890-2128-1, XP009553333-
OPPOSITION- Thomas A. Boyd, Chun-Su Yuan, "Chapter 10. Methylnaltrexone: Investigations in Treating Opioid Bowel Dysfunction", Handbook of Opioid Bowel Syndrome, US, The Haworth Medical Press, (20050101), pages 197 - 221, ISBN 978-0-7890-2128-1, XP009553336-
OPPOSITION- Chun-Su Yuan; Joseph F. Foss, "Oral Methylnaltrexone for Opioid-Induced Constipation", JAMA, American Medical Association, (20000920), vol. 284, no. 11, doi:10.1001/jama.284.11.1378, ISSN 0098-7484, pages 1383 - 1384, XP055457414
OPPOSITION- Jurna I; Baldauf J, "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.]​", Der Schmertz, DE , (19931201), vol. 7, no. 4, doi:10.1007/BF02529868, ISSN 0932-433X, pages 314 - 321, XP009176556
OPPOSITION- Jurna I; Baldauf J, "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.]​", Der SCHMERZ, DE , (19931201), vol. 7, no. 4, doi:10.1007/BF02529868, ISSN 0932-433X, pages 314 - 321, XP009176556
OPPOSITION- Jurna I; Baldauf J, "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.]​", SCHMERZ, Der, DE , (19931201), vol. 7, no. 4, doi:10.1007/BF02529868, ISSN 0932-433X, pages 314 - 321, XP009176556
OPPOSITION- Jurna I; Baldauf J, "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.]​", SCHMERZ, Der, SPRINGER VERLAG, BERLIN,, DE, DE , (19931201), vol. 7, no. 4, doi:10.1007/BF02529868, ISSN 0932-433X, pages 314 - 321, XP009176556
OPPOSITION- L. Latasch, M. Zimmermann, B. Eberhardt, I. Jurna, "Aufhebung einer Morphin- induzierten Obstipation durch orales Naloxon", Der Anaesthesist, Springer, (19970324), vol. 46, no. 3, doi:10.1007/s001010050390, ISSN 00032417, pages 191 - 194, XP055104659
OPPOSITION- SYKES N. P., "ORAL NALOXOME IN OPIOID-ASSOCIATED CONSTIPATION.", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19910615), vol. 337., doi:10.1016/0140-6736(91)93162-3, ISSN 0140-6736, page 1475., XP000654129
OPPOSITION- Smith, K. ; Hopp, M. ; Mundin, G. ; Leyendecker, P. ; Bailey, P. ; Grothe, B. ; Uhl, R. ; Reimer, K., "Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers", Clinical Therapeutics, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20081101), vol. 30, no. 11, doi:10.1016/j.clinthera.2008.11.008, ISSN 0149-2918, pages 2051 - 2068, XP025816491
OPPOSITION- Winfried Meissner , Petra Leyendecker, Stefan Mueller-Lissner, Joachim Nadstawek, Michael Hopp, Christian Ruckes, Stefan Wirz, Wolfgang Fleischer, Karen Reimer, "A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation", European Journal of pain, GB , (20090101), vol. 13, no. 1, doi:10.1016/j.ejpain.2008.06.012, ISSN 1090-3801, pages 56 - 64, XP025865529
OPPOSITION- Marco Pappagallo, M D, "Incidence, Prevalence, and Management of Opioid Bowel Dysfunction", The American Journal of Surgery, Excerpta Medica, (20011101), vol. 182, no. 5, doi:10.1016/S0002-9610(01)00782-6, ISSN 00029610, pages S11 - S18, XP055195525
OPPOSITION- Winfried Meissner, Uta Schmidt, Michael Hartmann, Roland Kath, Konrad Reinhart, "Oral naloxone reverses opioid-associated constipation", Pain, NL , (20000101), vol. 84, no. 1, doi:10.1016/S0304-3959(99)00185-2, ISSN 0304-3959, pages 105 - 109, XP055252526
OPPOSITION- Maywin Liu, Eric Wittbrodt, "Low-Dose Oral Naloxone Reverses Opioid-Induced Constipation and Analgesia", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT., ELSEVIER, NEW YORK, NY., US, US , (20020101), vol. 23, no. 1, doi:10.1016/S0885-3924(01)00369-4, ISSN 0885-3924, pages 48 - 53, XP055252523
OPPOSITION- N. D. Hawkes; C. Richardson; B. K. Evans; J. Rhodes; S. J. Lewis; G. A. O. Thomas, "Effect of an enteric‐release formulation of naloxone on intestinal transit in volunteers taking codeine", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE., GB, GB , (20020115), vol. 15, no. 5, doi:10.1046/j.1365-2036.2001.00970.x, ISSN 0269-2813, pages 625 - 630, XP071538521
OPPOSITION- N. D. Hawkes; C. Richardson; B. K. Evans; J. Rhodes; S. J. Lewis; G. A. O. Thomas, "Effect of an enteric‐release formulation of naloxone on intestinal transit in volunteers taking codeine", Alimentary Pharmacology & Therapeutics, GB , (20020115), vol. 15, no. 5, doi:10.1046/j.1365-2036.2001.00970.x, ISSN 0269-2813, pages 625 - 630, XP071538521
OPPOSITION- N. D. Hawkes; C. Richardson; B. K. Evans; J. Rhodes; S. J. Lewis; G. A. O. Thomas, "Effect of an enteric‐release formulation of naloxone on intestinal transit in volunteers taking codeine", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, GB , (20020115), vol. 15, no. 5, doi:10.1046/j.1365-2036.2001.00970.x, ISSN 0269-2813, pages 625 - 630, XP071538521
OPPOSITION- N D Hawkes , C Richardson, B K Evans, J Rhodes, S J Lewis, G A Thomas, "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine", Alimentary Pharmacology & Therapeutics, GB , (20010501), vol. 15, no. 5, doi:10.1046/j.1365-2036.2001.00970.x, ISSN 0269-2813, pages 625 - 630, XP055408359
OPPOSITION- B. Baierl, "Intelligente Schmerztherapie - Hohe Analgesie bei gleichzeitiger Regulation der Darmtätigkeit", NOTFALL & HAUSARZTMEDIZIN, DE , (20061001), vol. 32, no. 10, doi:10.1055/s-2006-956968, ISSN 1612-8583, page 466, XP055583687
OPPOSITION- B. Baierl, "Intelligente Schmerztherapie - Hohe Analgesie bei gleichzeitiger Regulation der Darmtätigkeit", Notfall & Hausarztmedizin, DE , (20061001), vol. 32, no. 10, doi:10.1055/s-2006-956968, ISSN 1612-8583, pages 466 - 466, XP055583687
OPPOSITION- B. Baierl, "Intelligente Schmerztherapie - Hohe Analgesie bei gleichzeitiger Regulation der Darmtätigkeit", NOTFALL & HAUSARZTMEDIZIN, DEMETER IM GEORG-THIEME-VERLAG, STUTTGART, DE, DE , (20061001), vol. 32, no. 10, doi:10.1055/s-2006-956968, ISSN 1612-8583, pages 466 - 466, XP055583687
OPPOSITION- Clopper , C J, E S Pearson , "The use of confidence or fiducial limits illustrated in the case of the binomial ", Biometrika, (19341130), vol. 26, no. 4, doi:10.1093/biomet/26.4.404, pages 404 - 413, XP093094306
OPPOSITION- Sykes Np, "An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer.", Palliative Medicine, (19960401), vol. 10, no. 2, doi:10.1177/026921639601000208, pages 135 - 144, XP055298264
OPPOSITION- Ueberall Michael, Eberhardt Alice, Mueller-Schwefe Gerhard, "Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice", INTERNATIONAL JOURNAL OF GENERAL MEDICINE, Dove Medical Press Ltd., GB, GB , (20160224), vol. 9, doi:10.2147/IJGM.S94685, ISSN 1178-7074, pages 39 - 51, XP093149546

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents